Zhang Ye, Hong Ying-Kai, Zhuang Dong-Wu, He Xue-Jun, Lin Ming-En
Department of Urology, the First affiliated hospital of Medical College Shantou University, 57 Changping Road, Shantou, Guangdong, China.
Medicine (Baltimore). 2019 Nov;98(44):e17725. doi: 10.1097/MD.0000000000017725.
Bladder cancer (BC) is a common malignancy associated with high morbidity and mortality, however, accurate and convenient risk assessment tools applicable to BC patients are currently lacking. Previous studies using nomograms to evaluate bladder cancer (BC) survival have been based on small samples. Using a large dataset, this study aimed to construct more precise clinical nomograms to effectively predict bladder cancer survival.Data on patients with pathologically-confirmed bladder cancer were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Additional BC patient data for an external validation cohort were extracted from the Cancer Genome Atlas (TCGA) database. Clinical parameters that constituted potential risk factors were reviewed and analyzed using univariate and multivariate Cox proportional hazards regression. A nomogram was constructed with parameters that significantly correlated with the overall survival (OS). Prognostic performance of a nomogram was assessed using the concordance index (c-index), area under the receiver operating characteristic curve (AUC), and a calibration curve. The model was then tested with data from an internal and external validation cohort. Patients' survival was analyzed and compared with the Kaplan-Meier (KM) method.Multivariate Cox regression showed that age, sex, race, stage_T1, stage_T2a, stage_T2b, stage_T3a, stage_Ta, stage_Tis, stage_N, stage_M were independent predictors of BC survival. A nomogram was constructed based on these factors. The c-index of the nomogram was 0.7916 (95% confidence interval CI, 0.79-0.80). The calibration curve showed excellent agreement between the predicted and observed values. The c-index for the internal validation cohort was 0.7917 (95% CI 0.79-0.80), which was higher than for the training cohort, suggesting robustness of the model. For the training cohort, the AUC for the 3- and the 5-year survival was 0.82 and 0.813, respectively. The c-index for the TNM-based model was superior to that for the AJCC-TNM classification.The models presented in this study might be suitable for clinical use, supporting clinicians in their individualized assessment of expected survival in BC patients. They might also be used as a layered tool for clinical research.
膀胱癌(BC)是一种常见的恶性肿瘤,发病率和死亡率都很高,然而,目前缺乏适用于膀胱癌患者的准确且便捷的风险评估工具。以往使用列线图评估膀胱癌(BC)生存率的研究都是基于小样本。本研究利用一个大型数据集,旨在构建更精确的临床列线图,以有效预测膀胱癌患者的生存率。
从监测、流行病学和最终结果(SEER)数据库中提取经病理确诊的膀胱癌患者的数据。从癌症基因组图谱(TCGA)数据库中提取用于外部验证队列的额外膀胱癌患者数据。使用单因素和多因素Cox比例风险回归对构成潜在风险因素的临床参数进行回顾和分析。用与总生存期(OS)显著相关的参数构建列线图。使用一致性指数(c指数)、受试者工作特征曲线下面积(AUC)和校准曲线评估列线图的预后性能。然后用来自内部和外部验证队列的数据对模型进行检验。采用Kaplan-Meier(KM)方法分析和比较患者的生存率。
多因素Cox回归显示,年龄、性别、种族、T1期、T2a期、T2b期、T3a期、Ta期、Tis期、N分期、M分期是膀胱癌生存率的独立预测因素。基于这些因素构建了列线图。列线图的c指数为0.7916(95%置信区间CI,0.79 - 0.80)。校准曲线显示预测值与观察值之间具有良好的一致性。内部验证队列的c指数为0.7917(95%CI 0.79 - 0.80),高于训练队列,表明模型具有稳健性。对于训练队列,3年和5年生存率的AUC分别为0.82和0.813。基于TNM的模型的c指数优于美国癌症联合委员会(AJCC)-TNM分类的c指数。
本研究中提出的模型可能适用于临床应用,有助于临床医生对膀胱癌患者的预期生存期进行个体化评估。它们也可能用作临床研究的分层工具。